Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,450,368
  • Shares Outstanding, K 1,765,882
  • Annual Sales, $ 45,804 M
  • Annual Income, $ 4,616 M
  • 60-Month Beta 0.83
  • Price/Sales 4.18
  • Price/Cash Flow 7.89
  • Price/Book 14.52
Trade ABBV with:

Options Overview

Details
  • Implied Volatility 26.50%
  • Historical Volatility 22.03%
  • IV Percentile 33%
  • IV Rank 19.44%
  • IV High 80.13% on 03/12/20
  • IV Low 0.09% on 12/17/20
  • Put/Call Vol Ratio 0.43
  • Today's Volume 10,989
  • Volume Avg (30-Day) 28,632
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 249,011
  • Open Int (30-Day) 280,141

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 2.76
  • Number of Estimates 7
  • High Estimate 3.01
  • Low Estimate 2.14
  • Prior Year 2.42
  • Growth Rate Est. (year over year) +14.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.15 +3.11%
on 02/12/21
110.27 -3.55%
on 02/05/21
-0.59 (-0.55%)
since 02/03/21
3-Month
101.55 +4.74%
on 12/21/20
113.41 -6.22%
on 01/13/21
+1.62 (+1.55%)
since 12/03/20
52-Week
62.55 +70.04%
on 03/23/20
113.41 -6.22%
on 01/13/21
+18.79 (+21.46%)
since 03/03/20

Most Recent Stories

More News
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

LLY : 202.72 (-0.70%)
AMGN : 223.47 (-0.98%)
ABBV : 106.49 (-1.26%)
BHVN : 79.75 (-3.53%)
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

LXRX : 7.40 (-0.40%)
RGEN : 203.41 (-4.35%)
ABBV : 106.49 (-1.26%)
RETA : 132.15 (+2.18%)
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout

Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion

SNY : 45.57 (-0.81%)
AZN : 47.14 (-1.24%)
PFE : 34.19 (+2.03%)
MRK : 73.09 (+0.33%)
GSK : 34.15 (+0.18%)
BAYRY : 15.6000 (-1.39%)
ABBV : 106.49 (-1.26%)
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

LXRX : 7.40 (-0.40%)
ABBV : 106.49 (-1.26%)
EDIT : 44.18 (-3.30%)
NBRV : 1.9800 (+2.59%)
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

, /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine...

AGN : 193.02 (+0.02%)
ABBV : 106.49 (-1.26%)
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA (adalimumab) for the treatment of moderately to severely active ulcerative colitis...

ABBV : 106.49 (-1.26%)
AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across Canada

AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across Canada

ABBV : 106.49 (-1.26%)
Psoriasis Treatment Market Size Anticipated to Hit USD 37,634.2 Million with 9.2% CAGR by 2026; Rising Prevalence of Psoriasis Worldwide will Promote Growth | Fortune Business Insights(TM)

The global psoriasis treatment market size is anticipated to touch USD 37,634.2 million by 2026 owing to the increasing number of psoriasis cases. Some studies say that psoriasis may further develop other...

ABBV : 106.49 (-1.26%)
LLY : 202.72 (-0.70%)
MRK : 73.09 (+0.33%)
PFE : 34.19 (+2.03%)
2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility

Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...

MSFT : 229.23 (-1.98%)
NKE : 135.33 (-1.23%)
AAPL : 123.52 (-1.28%)
SBUX : 107.75 (+0.51%)
MCD : 207.80 (-0.42%)
DIS : 194.56 (+0.32%)
LLY : 202.72 (-0.70%)
KO : 50.32 (+0.44%)
PEP : 129.83 (-0.95%)
TSLA : 678.42 (-1.17%)
ABBV : 106.49 (-1.26%)
KDP : 31.08 (+0.97%)
ZM : 348.08 (-6.63%)
New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use

, /PRNewswire/ -- From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are spending approximately 13 hours a day...

ABBV : 106.49 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

3rd Resistance Point 110.45
2nd Resistance Point 109.92
1st Resistance Point 108.88
Last Price 106.56
1st Support Level 107.31
2nd Support Level 106.78
3rd Support Level 105.74

See More

52-Week High 113.41
Last Price 106.56
Fibonacci 61.8% 93.98
Fibonacci 50% 87.98
Fibonacci 38.2% 81.98
52-Week Low 62.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar